LINCOMYCIN Drug Patent Profile
✉ Email this page to a colleague
When do Lincomycin patents expire, and when can generic versions of Lincomycin launch?
Lincomycin is a drug marketed by Geneyork Pharms, Gland Pharma Ltd, Micro Labs, Slate Run Pharma, Watson Labs, and Xgen Pharms. and is included in six NDAs.
The generic ingredient in LINCOMYCIN is lincomycin hydrochloride. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the lincomycin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lincomycin
A generic version of LINCOMYCIN was approved as lincomycin hydrochloride by XGEN PHARMS on June 4th, 2015.
Summary for LINCOMYCIN
US Patents: | 0 |
Applicants: | 6 |
NDAs: | 6 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for LINCOMYCIN |
DailyMed Link: | LINCOMYCIN at DailyMed |
Recent Clinical Trials for LINCOMYCIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sunnybrook Health Sciences Centre | Phase 4 |
Berry Consultants | Phase 4 |
University of Melbourne | Phase 4 |